Figure 2.
Linear mixed model trajectory of motor function in patients with SMA types 1, 2 and 3 treated with nusinersen. Motor function trajectories analysed with a linear mixed model with repeated measures, including bootstrapping (n = 1000) to estimate 95% confidence intervals. The grey lines represent individual trajectories. The red line and grey area reflect the mean changes in motor function over time with confidence interval, respectively. (A) Change from baseline in CHOP-INTEND score in all patients with SMA type 1 during treatment. (B) Change from baseline in HINE-2 score in patients with SMA type 1 during treatment. (C) Change from baseline in HFMSE score in patients with SMA type 2 during treatment. (D) Change from baseline in HFMSE score in patients with SMA type 3a during treatment.